In a recent study, Zavareh and co-workers (2021) demonstrated that HSP90 inhibition by ganetespib reduces surface expression of PD-L1 on MC-38 tumor cells and human monocyte-derived macrophages (75). Here, HSP90AB1 is linked to neoplasm.